Salarius Pharmaceuticals, LLC
Salarius is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. They focus on technologies that correct dysregulated gene expression in cancer cells, developing targeted protein inhibitors and degraders to address gene dysregulation in cancers such as leukemias and lymphomas. The company has received significant funding including a $16.1 million CPRIT award and support from the National Pediatric Cancer Foundation. Located in Houston, Texas, Salarius aims to advance its drugs to positively impact cancer patients.
Industries
Nr. of Employees
small (1-50)
Salarius Pharmaceuticals, LLC
Houston, Texas, United States, North America
Patents
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US-11820720-B2
View DetailsDeuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same
US-11773080-B2
View Details3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US-11040925-B2
View Details3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US-10202316-B2
View Details
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US-11820720-B2
View DetailsDeuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same
US-11773080-B2
View Details3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US-11040925-B2
View Details3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US-10202316-B2
View DetailsProducts
Targeted protein inhibitor program in early clinical development
An oncology small‑molecule inhibitor program progressed to Phase 1/2 clinical studies to evaluate safety and preliminary efficacy.
Targeted protein degrader program in IND‑enabling studies
A small‑molecule degraders program undergoing IND‑enabling preclinical studies to support regulatory filing and first‑in‑human dosing.
Targeted protein inhibitor program in early clinical development
An oncology small‑molecule inhibitor program progressed to Phase 1/2 clinical studies to evaluate safety and preliminary efficacy.
Targeted protein degrader program in IND‑enabling studies
A small‑molecule degraders program undergoing IND‑enabling preclinical studies to support regulatory filing and first‑in‑human dosing.
Services
Discovery and preclinical development activities for oncology candidates, including target validation and pharmacology studies.
Discovery and preclinical development activities for oncology candidates, including target validation and pharmacology studies.
Expertise Areas
- Targeted protein inhibition
- Targeted protein degradation
- Clinical trial management (Phase 1/2)
- IND‑enabling development and regulatory preparation
Key Technologies
- Targeted protein inhibitors (small molecules)
- Targeted protein degraders (small‑molecule degraders)
- Gene expression modulation approaches
- Preclinical tumor models
News & Updates
Event held in Boston, MA with a webinar link.
Participation in the EHA 2023 Hybrid Congress.
A recent study demonstrating the role of Seclidemstat in inhibiting LSD1, an oncology target.
An announcement about expanding their pipeline via acquisition.
Recipient of a three-year $16.1 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award
Received funding support for product development.
Support from the National Pediatric Cancer Foundation
Financial and in-kind support for their research and development.
Event held in Boston, MA with a webinar link.
Participation in the EHA 2023 Hybrid Congress.
A recent study demonstrating the role of Seclidemstat in inhibiting LSD1, an oncology target.
An announcement about expanding their pipeline via acquisition.
Recipient of a three-year $16.1 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award
Received funding support for product development.
Support from the National Pediatric Cancer Foundation
Financial and in-kind support for their research and development.